WHO Clears the First-Ever Malaria Treatment Made Specifically for Newborns and Tiny Infants

<p>One of the most vulnerable groups in global medicine has just gained something it has never had before: a malaria treatment built specifically for them.</p><p>On <strong>April 24, 2026</strong>, the <strong>World Health Organization</strong> announced the prequalification of the <strong>first-ever malaria treatment developed for newborns and young infants weighing between 2 and 5 kilograms</strong>. Until now, babies this small were often treated with formulations designed for older children, increasing the risk of dosing errors, side effects, and toxicity.</p><h2>Why this matters</h2><p>WHO said the new formulation, <strong>artemether-lumefantrine</strong>, helps close a long-standing treatment gap affecting some of the youngest patients in malaria-endemic regions. Prequalification means the medicine meets international standards for quality, safety, and efficacy, and it opens the door to broader public-sector procurement.</p><p>That matters enormously in Africa, where malaria still claims huge numbers of young lives and where roughly <strong>30 million babies are born every year in malaria-endemic areas</strong>.</p><h2>A bigger wave of progress</h2><p>The announcement came ahead of World Malaria Day and alongside new WHO-prequalified diagnostic tests designed to catch malaria strains that can evade some older rapid tests. WHO says those advances add to a growing arsenal that now includes vaccines, next-generation mosquito nets, better diagnostics, and more targeted medicines.</p><p>In other words, this is not just one new drug. It is another sign that malaria control is still moving forward, even against a disease that has burdened humanity for centuries.</p><p><em>Sources: World Health Organization, Novartis</em></p>